Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactionsMichael R. Filbin, Marcia B. Goldberg|Cell Reports Medicine|2021Cited by 309
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Andrew M. Vekstein et al.|The Lancet Respiratory Medicine|2022Cited by 127
Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patientsMichael R. Filbin, Marcia B. Goldberg|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 49